Teva Q4 2020 Earnings Report
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported flat revenues of $4,454 million for Q4 2020 compared to Q4 2019, with GAAP EPS at $0.14 and non-GAAP EPS at $0.68. The company met its 2020 financial guidance and saw minimal impact on its supply chain, R&D programs and product launches despite the COVID-19 pandemic.
Teva met all components of its 2020 financial guidance, following a strong fourth quarter performance.
Key growth drivers such as AUSTEDO and TRUXIMA delivered promising results and milestones.
Generic performance was boosted by the successful launch of generic versions of HIV-1 treatments Truvada and Atripla in the U.S.
Teva took steps to strengthen its biopharmaceutical pipeline, with a biosimilar commercialization agreement, and is advancing other pipeline assets.
Teva
Teva
Forward Guidance
Teva provided its 2021 outlook, expecting revenues between $16.4 and $16.8 billion and non-GAAP EPS between $2.50 and $2.70.
Positive Outlook
- Revenues are expected to be $16.4 - $16.8 billion
- COPAXONE revenue expected to be ~$1,050 million
- AUSTEDO revenue expected to be ~$950 million
- AJOVY revenue expected to be ~$300 million
- Non-GAAP EPS is expected to be $2.50 - $2.70